Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era

Sexual Health

Volumn 7, Issue 3, 2010, Pages 376-382

  Tota, Joseph ^a   Mahmud, Salaheddin M ^a,d   Ferenczy, Alex ^a,b   Coutĺe, Fraņois ^a,c   Franco, Eduardo L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF MANITOBA   (Canada)

Author keywords

cytology; HPV DNA; Pap smear

Indexed keywords

WART VIRUS VACCINE;

ALGORITHM; ARTICLE; CANCER GRADING; CANCER SCREENING; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; CYTOLOGY; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE MARKER; DRUG EFFICACY; FOLLOW UP; GENITAL TRACT INFECTION; HUMAN; LIQUID BASED CYTOLOGY; MASS SCREENING; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; PREVALENCE; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DISEASE; UTERINE CERVIX DYSPLASIA; VACCINATION; WART VIRUS;

CANADA; COST CONTROL; DNA PROBES, HPV; FEMALE; HUMANS; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; SEXUALLY TRANSMITTED DISEASES, VIRAL; UNNECESSARY PROCEDURES; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 77956013684     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH10022     Document Type: Article

References (47)

1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah K, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.doi:10.1002/(SICI)1096-9896(199909)189:13.0.CO;2-F
2. Franco EL, Rohan TE, Villa LL. Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999; 91: 506-511 doi:10.1093/jnci/91.6.506
3. Munoz N, Bosch FX, Castellsague X, Díaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-285 doi:10.1002/ijc.20244 (Pubitemid 38924707)
4. Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent l1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-1255 doi:10.1016/S0140-6736(06)68439-0
5. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 1928-1943 doi:10.1056/NEJMoa061760 (Pubitemid 46740303)
6. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10: 1915-1923
7. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359: 821-832 doi:10.1056/NEJMsa0707052
8. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290: 781-789 doi:10.1001/jama.290.6.781 (Pubitemid 37432955)
9. Rogoza RM, Ferko N, Bentley J, Meijer CJLM, Berkhof J, Wang K-L, et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. Vaccine 2008; 26: F46-58. doi:10.1016/j.vaccine.2008.02.039
10. Brisson M, Van De Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007; 25: 5399-5408 doi:10.1016/j.vaccine. 2007.04.086
11. Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med 2009; 151: 538-545
12. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96: 604-615 doi:10.1093/jnci/djh104
13. Miller AB, Nazeer S, Fonn S, Brandup-Lukanow A, Rehman R, Cronje H, et al. Report on consensus conference on cervical cancer screening and management. Int J Cancer 2000; 86: 440-447 doi:10.1002/(SICI)1097-0215(20000501)86:33.0. CO;2-A
14. Franco EL, Mahmud SM, Tota J, Ferenczy A, Coutlee F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res 2009; 40: 478-485 doi:10.1016/j.arcmed.2009.06.003
15. Sargent A, Bailey A, Almonte M, Turner A, Thomson C, Peto J, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008; 98: 1704-1709 doi:10.1038/sj.bjc.6604324 (Pubitemid 351684674)
16. Coupé VM, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ. Agedependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008; 98: 646-651 doi:10.1038/sj.bjc.6604162 (Pubitemid 351214513)
17. Franco EL, Cuzick J, Hildesheim A, De Sanjose S. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006; 24: 171-177 doi:10.1016/j.vaccine.2006.05.061 (Pubitemid 44293022)
18. Cuzick J, Clavel C, Petry KU, Meijer CJLM, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119: 1095-1101 doi:10.1002/ijc.21955 (Pubitemid 44116919)
19. Nanda K, Mccrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132: 810-819
20. Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008; 26: A16-23. doi:10.1016/j. vaccine.2007.11.069 (Pubitemid 351312311)
21. Ratnam S, Franco EL, Ferenczy A. Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prev 2000; 9: 945-951
22. Mayrand MH, Duarte-Franco E, Coutlee F, Rodrigues I, Walter SD, Ratnam S, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian Cervical Cancer Screening Trial (CCCaST). Int J Cancer 2006; 119: 615-623 doi:10.1002/ijc.21897 (Pubitemid 43955716)
23. Sankaranarayanan R, Thara S, Esmy PO, Basu P. Cervical cancer: screening and therapeutic perspectives. Med Princ Pract 2008; 17: 351-364 doi:10.1159/000141498
24. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008; 111: 167-177
25. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of metaanalyses. Vaccine 2006; 24(Suppl 3): 78-89. doi:10.1016/j.vaccine. 2006.05.117
26. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009; 101: 88-99. doi:10.1093/jnci/djn444
27. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJP, Zandwijken GRJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44 102 women. Int J Cancer 2004; 110: 94-101. doi:10.1002/ ijc.20076
28. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJP, Bulk S, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370: 1764-72. doi:10.1016/S01 40-6736(07)61450-61460
29. Elfgren K, Rylander E, Radberg T, Strander B, Strand A, Paajanen K, et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 2005; 193: 650-657 doi:10.1016/j.ajog.2005.01. 056 (Pubitemid 41261457)
30. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005; 93: 862-7.doi:10.1038/sj.bjc.6602799 (Pubitemid 41487010)
31. Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360: 1385-1394 doi:10.1056/NEJMoa0808516
32. Kitchener HC, Almonte M, Thomson C, Wheeler P, Sargent A, Stoykova B, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomized controlled trial. Lancet Oncol 2009; 10: 672-682 doi:10.1016/S1470-2045(09)70156-1
33. Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009; 101: 1612-1623 doi:10.1093/jnci/ djp367
34. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006; 7: 547-555 doi:10.1016/S1470- 2045(06)70731-8 (Pubitemid 43923665)
35. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100: 492-501. doi:10.1093/jnci/djn065
36. Naucler P, Ryd W, Tornberg S, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-1597 doi:10.1056/ NEJMoa073204 (Pubitemid 47598401)
37. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-1588 doi:10.1056/ NEJMoa071430
38. Bulkmans NW, Berkhof J, Bulk S, Bleeker MCG, van Kemenade FJ, Rozendaal L, et al. High-risk HPV type-specific clearance rates in cervical screening. Br J Cancer 2007; 96: 1419-1424 http:// www.nature.com/bjc/journal/v96/n9/full/ 6603653a.html - aff1#aff1.doi:10.1038/sj.bjc.6603653
39. Dillner J, Rebolj M, Birembaut P, Petry K-U, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754. doi:10.1136/bmj.a1754
40. Coutlee F, Rouleau D, Ferenczy A, Franco E. The laboratory diagnosis of genital human papillomavirus infections. Canadian J Infect Dis Med Microbiol 2005; 16: 83-91.
41. Depuydt CE, Arbyn M, Benoy IH, Vandepitte J, Vereecken AJ, Bogers JJ. Quality control for normal liquid based cytology: rescreening, high risk HPV targeted reviewing and/or high risk HPV detection? J Cell Mol Med 2009; 13: 4051-4060
42. Franco EL. A new generation of studies of human papillomavirus DNA testing in cervical cancer screening. J Natl Cancer Inst 2009; 101: 1600-1601 doi:10.1093/jnci/djp392
43. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand M-H, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008; 26(Suppl. 10): K29-41.doi:10.1016/j.vaccine.2008.06.019
44. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009; 339: b2968. doi:10.1136/bmj.b2968
45. Saslow D, Runowicz CD, Solomon D, Moscicki A-B, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52: 342-362 doi:10.3322/canjclin.52.6.342 (Pubitemid 35446606)
46. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007; 197: 346-355 doi:10.1016/j.ajog.2007.07.047
47. Spitzer M. Screening and management of women and girls with human papillomavirus infection. Gynecol Oncol 2007; 107: S14-8.doi:10.1016/j.ygyno. 2007.07.069 (Pubitemid 47552536)